荷丹片联合阿托伐他汀对伴有睡眠呼吸暂停的脑梗死患者血脂及炎症因子的影响

Abstract
Figure/Table
References (21)
Related Citation (3)

Download: PDF (614 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract] Objective To investigate the effects of Hedan Tablets combined with Atorvastatin for serum lipids and inflammatory factors of cerebral infarction with sleep apnea-hypopnea patients. Methods Total 74 cases of cerebral infarction with sleep apnea-hypopnea patients admitted to the Affiliated Hospital of Hebei University from January 2013 to June 2015 were selected as research objects. The patients were randomly divided into control group (n = 37) and observation group (n = 37). The control group was treated with oral administration of Atorvastatin for 4 weeks, the observation group was treated with oral administration of Hedan Tablets combined with Atorvastatin for 4 weeks. Before and after treatment the serum triglyceride (TG), total cholesterol (TC), low density lipoprotein C (LDL-C), high-sensitivity C-reactive protein (hs-CRP) and soluble intercellular adhesion molecules-1 (sICAM-1) were determined. Results After treatment, the levels of serum TG [(2.549±0.441), (2.854±0.444) mmol/L], TC[(2.865±1.035), (2.992±0.991) mmol/L], LDL-C[(1.778±0.486), (1.827±0.527) mmol/L], hs-CRP[(1.846±0.607), (2.230±0.799) mg/L] and sICAM-1[(315.532±39.717), (345.108±30.733) ng/mL] in observation group and control group were all lower than those [(3.630±0.548), (3.862±0.683) mmol/L;(5.878±0.999), (5.757±1.062) mmol/L; (3.687±0.581), (3.538±0.658) mmol/L; (4.500±1.432), (4.422±1.540) mg/L; (397.762±33.752), (409.243±39.001) ng/mL] before treatment, the differences were all statistically significant (P < 0.01). After treatment, there were no statistically significant differences of the levels of serum TC and LDL-C between observation group and control group (P > 0.05). The levels of serum TG, hs-CRP and sICAM-1 in control group were lower than those of observation group after treatment, the differences were statistically significant (P < 0.05 or P < 0.01). Conclusion Hedan Tablets combined with atorvastatin has strong effects of lipid-lowering in cerebral infarction with sleep apnea-hypopnea patients. Hedan tablet combined with atorvastatincan strengthens the inflammatory response.

Key words： [Key words] Hedan Tablets Atorvastatin Sleep apnea-hypopnea Cerebral infarction High-sensitivity C-reactive protein sICAM-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Huixin1 LI Xiaofang1 WANG Chuhan1 ZHANG Zeming2 ZHANG Xinghong1▲

Cite this article:

ZHAO Huixin1 LI Xiaofang1 WANG Chuhan1 ZHANG Zeming2 ZHANG Xinghong1▲. Effect of Hedan Tablets combined with Atorvastatin on serum lipids and inflammatory factors in cerebral infarction with sleep apnea-hypopnea patients[J]. 中国医药导报, 2016, 13(3): 134-137，141.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2016/V13/I3/134

[参考文献]
[1] 袁远，高旭光.阻塞性睡眠呼吸暂停低通气综合征与急性脑梗死预后的关系研究[J].中国全科医学，2012，15（23）：2616-2618.
[2] 杨秀平，赵尧辉，冯玉婧，等.阻塞性睡眠呼吸暂停低通气综合征与脑梗死的关系[J].中国动脉硬化杂志，2015， 23（7）：713-716.
[3] Baessler A，Nadeem R，Harvey M，et al. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers-a meta-analysis [J]. J Inflamm，2013，10（1）：13.
[4] 王海楠.高血脂与慢性病、高血压、糖尿病、冠心病、脑梗死的关系[J].医学美学美容，2014，8：153.
[5] 侯永革，王菁，王俊刚，等.缺血性脑卒中患者血清PTX-3水平变化及阿托伐他汀的干预效果[J].河北医药，2014， 36（24）：3755-3757.
[6] 许岩.阿托伐他汀在治疗冠心病中的抗炎作用分析[J].中国实用医药，2015，10（20）：130-131.
[7] 胡媛媛.荷丹片痰瘀同治的临床应用[J].中西医结合心脑血管病杂志，2014，12（6）：767-768.
[8] 范英丽，朱叶，尹德辉.荷丹片联合阿托伐他汀治疗中青年血脂异常35例[J].医药导报，2014，33（8）：1029-1031.
[9] 于柏青，周玉娟，刘福林，等.荷丹片对APOE-/-小鼠炎症因子及氧化应激因子的影响[J].天津医药，2015，43（10）：1144-1146.
[10] 赵慧新，赵会媛，闫奕，等.急性脑梗死合并阻塞性睡眠呼吸暂停低通气综合征患者颈动脉内中膜厚度及血清基质金属蛋白酶9水平变化[J].中国全科医学，2014， 17（24）：2859-2861.
[11] 杨瑞，赵雅宁，李建民.低氧诱导因子-1与阻塞性睡眠呼吸暂停低通气综合征合并脑梗死患者认知功能的相关研究[J].现代预防医学，2015，42（3）：569-572.
[12] Elhage R，Jawien J，Rudling M，et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice [J]. Cardiovasc Res，2003，59（1）：234-240.
[13] Tan TY，Liou CW，Friedman M，et al. Factors associated with increased carotid intima-media thickness in obstructive sleep apnea/hypopnea syndrome [J]. Neurologist，2012，18（5）：277-281.
[14] 李亚楠.高脂血症并发脑梗死患者应用阿托伐他汀钙对血脂、颈动脉粥样硬化的影响[J].中外医学研究，2015， 13（18）：41-43.
[15] 韩迪，杨红灵.阿托伐他汀钙片联合中药治疗高脂血症的疗效观察[J].中医临床研究，2015，7（15）：47-48.
[16] 杨锡珍，杨国亮，苗少辉，等.超声评价荷丹片联合阿托伐他汀治疗颈动脉粥样硬化的疗效[J].河北医药，2013，35（18）：2766-2767.
[17] 李本华，宋鹰.荷丹片联合阿托伐他汀治疗高脂血症疗效观察[J].中西医结合心脑血管病杂志，2014，7（12）：806-807.
[18] 陈亚丽.荷丹片联合阿托伐他汀对颈动脉粥样硬化患者炎性细胞因子的干预影响[J].中西医结合心脑血管病杂志，2012，7（10）：808-810.
[19] 杨华清.大剂量阿托伐他汀对急性脑梗死血清炎症因子水平及颈动脉内膜中层厚度的影响[J].山东医药，2014， 54（23）：72-74.
[20] 程昌霞，周建华，曹武.冠心病患者血清胆红素、超敏C反应蛋白及同型半胱氨酸的表达及临床意义[J].中国医药导报，2014，11（13）：39-41.
[21] 张从虬，白宇.低分子肝素钠治疗急性脑梗死的临床分析中[J].国临床医学杂志，2000,7（2）：195.